Updated Jul 16, 2026
Sims Andrew John Hugh MacIntyre has filed 2 SEC Form 4 filings across 1 company in the last 90 days — buying. Lifetime open-market purchases: $10K.
Andrew John Sims Hugh Macintyre is the Chief Financial Officer of Plus Therapeutics, Inc., a clinical-stage pharmaceutical company focused on developing treatments for cancer and rare diseases. He has been involved in multiple SEC filings related to his role at the company.
| Role | Insider |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-01 | PSTV | PLUS THERAPEUTICS, INC. | M — Option exercise | 287 | $0.00 | |
| 2026-07-01 | PSTV | PLUS THERAPEUTICS, INC. | M — Option exercise | 1.2K | $0.00 | |
| 2026-07-01 | PSTV | PLUS THERAPEUTICS, INC. | M — Option exercise | 1.5K | $0.00 | |
| 2026-04-01 | PSTV | PLUS THERAPEUTICS, INC. | M — Option exercise | 29.1K | $0.00 | |
| 2026-04-01 | PSTV | PLUS THERAPEUTICS, INC. | M — Option exercise | 38.3K | $0.00 | |
| 2026-01-02 | PSTV | PLUS THERAPEUTICS, INC. | M — Option exercise | 38.3K | $0.00 | |
| 2025-11-05 | PSTV | PLUS THERAPEUTICS, INC. | P — Open-market purchase | 20.0K | $0.51 | $10K |
| 2025-10-01 | PSTV | PLUS THERAPEUTICS, INC. | M — Option exercise | 38.3K | $0.00 |
Andrew John Sims Hugh Macintyre is the Chief Financial Officer of Plus Therapeutics, Inc., a clinical-stage pharmaceutical company focused on developing treatments for cancer and rare diseases. He has been involved in multiple SEC filings related to his role at the company.…
2 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 1 open-market purchases ($10K) and 0 open-market sales () across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Sims Andrew John Hugh MacIntyre profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.